The present disclosure relates to crystalline polymorph and amorphous forms of 2-methyl-2-(3-methyl-4-(4-(methylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-1H-pyrazol-1-yl)propanenitrile or solvates, tautomers, and pharmaceutically acceptable salts or cocrystals thereof, and processes for their preparation.本發明係關於2-甲基-2-(3-甲基-4-(4-(甲胺基)-5-(三氟甲基)嘧啶-2-基胺基)-1H-吡唑-1-基)丙腈之結晶多晶型物及非晶形式或其溶劑合物、互變異構體及醫藥學上可接受之鹽或共晶及其製備方法。